Cerus Corporation (NASDAQ:CERS - Free Report) - Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of Cerus in a research report issued on Thursday, August 7th. Cantor Fitzgerald analyst R. Osborn anticipates that the biotechnology company will post earnings per share of ($0.10) for the year. The consensus estimate for Cerus' current full-year earnings is ($0.08) per share.
Cerus (NASDAQ:CERS - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The biotechnology company reported ($0.03) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.01). Cerus had a negative net margin of 9.81% and a negative return on equity of 33.77%. The firm had revenue of $60.10 million during the quarter, compared to analysts' expectations of $51.80 million.
Cerus Stock Performance
NASDAQ CERS opened at $1.21 on Monday. Cerus has a 1-year low of $1.12 and a 1-year high of $2.39. The company has a market capitalization of $231.96 million, a P/E ratio of -12.10 and a beta of 1.55. The business has a 50 day moving average price of $1.39 and a 200 day moving average price of $1.45. The company has a debt-to-equity ratio of 1.01, a current ratio of 2.00 and a quick ratio of 1.35.
Hedge Funds Weigh In On Cerus
Several hedge funds have recently bought and sold shares of the company. Acadian Asset Management LLC increased its position in Cerus by 38.6% during the second quarter. Acadian Asset Management LLC now owns 2,632,304 shares of the biotechnology company's stock worth $3,710,000 after buying an additional 733,683 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its position in Cerus by 49.2% during the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 296,099 shares of the biotechnology company's stock worth $418,000 after buying an additional 97,592 shares in the last quarter. Los Angeles Capital Management LLC increased its position in Cerus by 30.5% during the second quarter. Los Angeles Capital Management LLC now owns 367,389 shares of the biotechnology company's stock worth $518,000 after buying an additional 85,835 shares in the last quarter. Savant Capital LLC increased its position in Cerus by 339.6% during the second quarter. Savant Capital LLC now owns 94,812 shares of the biotechnology company's stock worth $134,000 after buying an additional 73,244 shares in the last quarter. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd increased its position in Cerus by 140.2% during the second quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 367,525 shares of the biotechnology company's stock worth $518,000 after buying an additional 214,515 shares in the last quarter. 78.37% of the stock is owned by hedge funds and other institutional investors.
Cerus Company Profile
(
Get Free Report)
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cerus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cerus wasn't on the list.
While Cerus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.